News zum Sektor Gesundheit aus Schweden

 

The Annual Report for Enzymatica 2025 has been published today (in Swedish) on the company's website: Finansiella rapporter - Enzymatica (https://www.enzymatica.com/sv/investerare/finansiella-rapporter/). The report is available only in digital format. An English summary is available at: Financial reports - Enzymatica (https://www.enzymatica.com/investors/financial-reports/)....

Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to the annual general meeting to be held on 19 May 2026 at 10:00 CEST at BAHR Advokatbyrå, Birger Jarlsgatan 16, in Stockholm. The registration to the meeting will open at 09:30 CEST. This notice is a translation of a Swedish notice and in case of any deviations between the language versions, the Swedish version shall prevail. Right to participate and notice of participation A shareholder who wishes to participate at the general meeting must: (i) be recorded in the share register...

Intervacc AB (publ) announces that the company's 2025 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on the company's website intervacc.com (https://intervacc.se/en/investors/reports/). For more information please contact:   Carl-Johan Dalsgaard, CEO Phone: +46 (0)8 120 10 600 E-mail: carl-johan.dalsgaard@intervacc.se   The information was submitted for publication, through the agency of the contact person set out above on April 14, 2026 at 08.30 CET. About...

Diamyd Medical today announced that it will discontinue the Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in Stage 3 type 1 diabetes. Following the previously reported interim analysis and subsequent evaluation of the interim results, including independent external statistical validation, the Company has concluded that the interim results meet the pre-specified futility criteria and do not support continuation. The interim analysis results, first announced on Friday March 27, were based on 174 evaluable participants followed from baseline to month 15. The results showed no...

Swiss contract drugmaker PolyPeptide Group AG is attracting potential takeover interest from private equity firms including EQT AB and KKR & Co., people with knowledge of the matter said....

The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Wednesday 13 May 2026 at 3.00 p.m. at Cirio Advokatbyrå, Biblioteksgatan 9, in Stockholm. Participation at the AGM Shareholders who wish to participate at the AGM must: · both be registered by own name (not nominee registered), in the register of shareholders maintained by Euroclear Sweden AB as per Tuesday 5 May 2026, · and notify their intention to participate to the Company in accordance with the instructions below, no later...

LUND, SE / ACCESS Newswire / April 10, 2026 / Alligator Bioscience (STO:ATORX)(Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody dru......

OssDsign AB (publ.) today announces that preliminary revenue for the period January – March, 2026 will be USD 4.035 million or SEK 36.880 million.  The company attributes these results to a lack of sales channel expansion in late 2025, departure of certain sales personnel, and temporary slowdowns in key accounts due to contract negotiations. According to preliminary data, sales of OssDsign Catalyst from January to March 2026 were USD 4.035 million, representing a decline of 3.6%, or SEK 36.880 million, representing a decline of 17.1%, compared to the same quarter in the previous year. The...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will participate at Nordic Health Summit Japan, April 23–24, 2026 in Tokyo, Japan, and ChinaBio Partnering Forum, April 28–29, 2026 in Shanghai, China. The events provide strategic platforms to advance partnering discussions with potential pharmaceutical partners and strengthen Cereno Scientific's growing presence in key Asian markets aiming to maximize the value of its HDAC inhibitor...

Onconetix shares are surging Thursday afternoon after the company highlighted a product milestone from Realbotix, the pending acquisition target it agreed to buy in an all-stock deal. Importance Rank:  2 read more...

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / April......

Vinci Enables Realbotix Robots to Recognize People, Recall Conversations, and Track Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp....

UPPSALA, SE / ACCESS Newswire / April 9, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB today announced that it has secured strategic contracts to supply hospitals within one of the world's la......

GOTHENBURG, Sweden, April 9, 2026 /PRNewswire/ -- Vitrolife AB (publ) will publish its Q1 2026 interim report on Thursday, 23 April 2026 at 08:00 am CET. A conference call for investors, analysts and financial media will be held at 10:00 am CET the same day. The presentation will be held......

SyntheticMR AB (publ) hereby announces that the Group´s Annual Report for 2025 has been published. The Annual Report is also available on SyntheticMRs website www.syntheticmr.com The English Annual Report is a translation of the Swedish version. The Swedish Annual Report shall prevail in case of conflict....

GOTHENBURG, SE / ACCESS Newswire / April 9, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that......

STOCKHOLM, SE / ACCESS Newswire / April 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Off......

Lund, Sweden, 8 April, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January - March 2026 on 23 April, 2026. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST / 8:00 AM EDT. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, Richard Philipson, CMO, and Maria Törnsén, COO and President U.S. During the call, management will review the Company's interim financial results and provide a business and pipeline update. The presentation will be held in English. Slides used in...

An Extraordinary general meeting of Diamyd Medical Aktiebolag (the “Company”) was held on April 8, 2026. The Extraordinary General Meeting resolved to approve the board of directors' resolution from March 23, 2026, to issue not more than 24,875,066 warrants, entailing an increase in the share capital of not more than SEK 2,522,860.285362 if all warrants are exercised. The issue constitutes the second tranche of the directed issuances announced by the Company on March 23, 2026. The right to subscribe for the new warrants shall, with deviation from the shareholder's pre-emptive rights, be...

Spermosens AB (“Spermosens” or the “Company”) announces that development of the JUNO-Checked Generation 3 system is now complete.  This innovative sensor system meets the performance standards necessary for a commercially viable product. The Company is preparing to initiate patient recruitment for a clinical validation study at the Reproductive Medicine Center (RMC) in Malmö. This represents a major milestone in the strategic plan to bring improved fertility diagnostics to the market through commercial partnerships. Significant improvements of JUNO-Checked Generation 3 The development of...